RATIO-SALBUTAMOL SOLUTION

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

SALBUTAMOL (SALBUTAMOL SULFATE)

Sẵn có từ:

TEVA CANADA LIMITED

Mã ATC:

R03AC02

INN (Tên quốc tế):

SALBUTAMOL

Liều dùng:

0.5MG

Dạng dược phẩm:

SOLUTION

Thành phần:

SALBUTAMOL (SALBUTAMOL SULFATE) 0.5MG

Tuyến hành chính:

INHALATION

Các đơn vị trong gói:

2.5ML

Loại thuốc theo toa:

Prescription

Khu trị liệu:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0108887009; AHFS:

Tình trạng ủy quyền:

CANCELLED POST MARKET

Ngày ủy quyền:

2019-07-09

Đặc tính sản phẩm

PRODUCT MONOGRAPH
RATIO-SALBUTAMOL
salbutamol sulphate nebules P.F. 1.25MG/2.5 ML, 5.0 MG/2.5 ML AMPOULES
Bronchodilator
(beta
2
-adrenergic stimulant)
TEVA CANADA LIMITED..
30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA, M1B 2K9
Control: 165512
DATE OF PREPARATION:
JULY 3, 2013
Teva Canada Limited.
2/32
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................................................
3
SUMMARY PRODUCT INFORMATION
.............................................................................................................
3
INDICATIONS AND CLINICAL USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
3
WARNINGS AND PRECAUTIONS
......................................................................................................................
3
ADVERSE REACTIONS
........................................................................................................................................
7
DRUG INTERACTIONS
.........................................................................................................................................
7
DOSAGE AND ADMINISTRATION
....................................................................................................................
10
OVERDOSAGE
.....................................................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
...................................................................................................
12
STORAGE AND STABILITY
...............................................................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................